CagriSema: a novel dual-pathway approach to target obesity and its complications

References

[1] GBD 2021 Adult BMI Collaborators. Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021 Lancet 2025 405 813 38 PMC11920007

[2] Beutler LR. GLP-1 physiology and pharmacology along the gut-brain axis J Clin Invest 2026 136 PMC12807470

[3] Drucker DJ. GLP-1-based therapies for diabetes, obesity and beyond Nat Rev Drug Discov 2025 24 631 50

[4] Becerril S,Frühbeck G. Cagrilintide plus semaglutide for obesity management Lancet 2021 397 1687 9

[5] Garvey WT,Blüher M,Osorto Contreras CK.et al. ; REDEFINE 1 Study Group. Coadministered cagrilintide and semaglutide in adults with overweight or obesity N Engl J Med 2025 393 635 47

[6] Arterburn DE,Telem DA,Kushner RF,Courcoulas AP. Benefits and risks of bariatric surgery in adults: a review JAMA 2020 324 879 87

[7] Wilding JPH,Batterham RL,Calanna S.et al. ; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity N Engl J Med 2021 384 989 1002

[8] Look M,Dunn JP,Kushner RF.et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight Diabetes Obes Metab 2025 27 2720 9 PMC11965027

[9] Neeland IJ,Linge J,Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies Diabetes Obes Metab 2024 26 16 27

[10] Secher A,Lutz TA,Raun K. The story of amylin: from physiology to therapy Nat Metab 2026 8 299 312

[11] Dacquin R,Davey RA,Laplace C.et al. Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo J Cell Biol 2004 164 509 14 PMC2171986

[12] Maleitzke T,Hildebrandt A,Dietrich T.et al. The calcitonin receptor protects against bone loss and excessive inflammation in collagen antibody-induced arthritis iScience 2022 25 103689 PMC8753130

[13] Davies MJ,Bajaj HS,Broholm C.et al. ; REDEFINE 2 Study Group. Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes N Engl J Med 2025 393 648 59

[14] Jastreboff AM,Aronne LJ,Ahmad NN.et al. ; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity N Engl J Med 2022 387 205 16

[15] Billings LK,Hsia S,Bays H.et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial Lancet 2025 406 2631 43

[16] le Roux CW,Wharton S,Startseva E.et al. ; SYNCHRONIZE-1 Investigators. Survodutide once weekly for the treatment of adults with obesity N Engl J Med 2026 Epub ahead of print

[17] Jastreboff AM,Ryan DH,Bays HE.et al. ; MariTide Phase 2 Obesity Trial Investigators. Once-monthly maridebart cafraglutide for the treatment of obesity - a phase 2 trial N Engl J Med 2025 393 843 57

[18] Jastreboff AM,Kaplan LM,Frías JP.et al. ; Retatrutide Phase 2 Obesity Trial Investigators. Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial N Engl J Med 2023 389 514 26

[19] Bajaj HS,Welch M,Shah P.et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial Lancet 2026 407 2402 13

[20] Tzeravini E,Simati S,Anastasiou IA,Dalamaga M,Kokkinos A. Gut peptide alterations in type 2 diabetes and obesity: a narrative review Curr Obes Rep 2026 15 8 PMC12830499

[21] Holm SK,Johansen VBI,Clemmensen C. LEAP2 as a therapeutic target in obesity and cardiometabolic disorders Rev Endocr Metab Disord 2026 27 687 704

[22] Holm SK,Johansen VBI,Ranea-Robles P.et al. Sustained weight loss with combined LEAP2 and semaglutide treatment in mice Diabetes 2025 74 2089 100 PMC12585159

[23] Englund A,Lange AH,Hagemann CA.et al. LEAP2 reduces ad libitum food intake and attenuates postprandial glucose excursions in men with obesity Diabetes 2026 75 925 37 PMC13191397

[24] Su QJ,Ashenhurst JR,Xu W.et al. ; 23andMe Research Team. Genetic predictors of GLP1 receptor agonist weight loss and side effects Nature 2026 653 770 5 PMC13175888